Moreover, the 36-month beta value for CRVS is 0.57. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRVS is 53.32M and currently, short sellers hold a 13.28% of that float. On June 25, 2025, CRVS’s average trading volume was 1.07M shares.
CRVS) stock’s latest price update
Corvus Pharmaceuticals Inc (NASDAQ: CRVS)’s stock price has gone rise by 994695 in comparison to its previous close of 3.73, however, the company has experienced a 1.88% increase in its stock price over the last five trading days. 247wallst.com reported 2025-06-11 that “The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
CRVS’s Market Performance
Corvus Pharmaceuticals Inc (CRVS) has experienced a 1.88% rise in stock performance for the past week, with a 25.07% rise in the past month, and a 2.12% rise in the past quarter. The volatility ratio for the week is 8.99%, and the volatility levels for the past 30 days are at 5.61% for CRVS. The simple moving average for the past 20 days is 8.32% for CRVS’s stock, with a -18.18% simple moving average for the past 200 days.
Analysts’ Opinion of CRVS
Many brokerage firms have already submitted their reports for CRVS stocks, with H.C. Wainwright repeating the rating for CRVS by listing it as a “Buy.” The predicted price for CRVS in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on January 02, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see CRVS reach a price target of $7. The rating they have provided for CRVS stocks is “Outperform” according to the report published on August 18th, 2023.
Jefferies gave a rating of “Buy” to CRVS, setting the target price at $8 in the report published on December 01st of the previous year.
CRVS Trading at 16.92% from the 50-Day Moving Average
After a stumble in the market that brought CRVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.60% of loss for the given period.
Stock Fundamentals for CRVS
The total capital return value is set at -0.62. Equity return is now at value -100.13, with -83.20 for asset returns.
Based on Corvus Pharmaceuticals Inc (CRVS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.74.
Currently, EBITDA for the company is -27.55 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
To wrap up, the performance of Corvus Pharmaceuticals Inc (CRVS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
